Chemisch modifizierte Peptidanaloga

Die vorliegende Erfindung betrifft verbesserte Mittel und Verfahren zur Behandlung von Diabetes und Alzheimer-Krankheit unter Verwendung von IAPP-Peptidderivaten.

DE1004051014 A UPAB: 20060809 NOVELTY - The islet amyloid polypeptide (IAPP) analog, with the ability to bond with natural IAPP receptors, has a maximum of 38 amino acids of which 37 residues follow the sequence of a natural IAPP and at least 19-37 have amino acids in a natural sequence. DETAILED DESCRIPTION - The islet amyloid polypeptide (IAPP) analog, with the ability to bond with natural IAPP receptors, has a maximum of 38 amino acids of which 37 residues follow the sequence of a natural IAPP and at least 19-37 have amino acids in a natural sequence. At least one of the amide bonds is N-methylated. Optionally natural lysine in position 1 can be replaced by ornithine, and/or cysteines at positions 2 and 7 can be replaced by diaminopropionic acid and asparagine acid, respectively, or vice versa. The peptide analogs have the sequence SEQ ID Nos.1-5 as defined in the specification. ACTIVITY - Antidiabetic; Neuroprotective; Nootropic. No biological data given. MECHANISM OF ACTION - None given. USE - The peptide derivative is for the treatment of diabetes and Alzheimer's disease. ADVANTAGE - The peptide derivative is in an isolated partially or wholly cleaned form, for an improved prophylaxis, therapy and diagnosis of diabetes and Alzheimer's disease.